Tandem Diabetes Care announced its Q2 2024 financial results, reporting a 13% increase in worldwide GAAP sales to $221.9 million. The company also launched Tandem Mobi with Dexcom G7 integration and completed enrollment for a Control-IQ study. Sales guidance for the full year 2024 has been increased.
Worldwide GAAP sales increased 13% to $221.9 million compared to Q2 2023.
More than 20,000 pumps were shipped in the United States, a sequential increase of 33% compared to Q1 2024.
Tandem Mobi with Dexcom G7 CGM sensor integration was launched in the United States.
Enrollment was completed for the Control-IQ pivotal study to support an expanded indication for people with type 2 diabetes.
Tandem Diabetes Care updated its 2024 financial guidance, estimating non-GAAP sales of approximately $885 million to $892 million for the full year. Non-GAAP gross margin is estimated to be approximately 51 percent, and adjusted EBITDA margin is expected to be breakeven.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance